Scarica l'app Stockscreener
3.52
0.28%
0.01
Dopo l'orario di chiusura:
3.52
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABCL Giù?
Forum
Previsione
Precedente Chiudi:
$3.51
Aprire:
$3.43
Volume 24 ore:
3.48M
Relative Volume:
0.89
Capitalizzazione di mercato:
$1.07B
Reddito:
$75.13M
Utile/perdita netta:
$-146.41M
Rapporto P/E:
-7.1778
EPS:
-0.4904
Flusso di cassa netto:
$-174.43M
1 W Prestazione:
+5.07%
1M Prestazione:
-7.85%
6M Prestazione:
-41.14%
1 anno Prestazione:
+58.56%
Intervallo 1D:
$3.41
$3.625
Intervallo di 1 settimana:
$3.2336
$3.67
Portata 52W:
$1.8906
$6.515
Abcellera Biologics Inc Stock (ABCL) Company Profile
Nome
Abcellera Biologics Inc
Settore
Industria
Telefono
(604) 559-9005
Indirizzo
150 W 4TH AVENUE, VANCOUVER
Compare ABCL vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
3.52 | 1.07B | 75.13M | -146.41M | -174.43M | -0.4904 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-07-07 | Ripresa | Leerink Partners | Outperform |
| 2024-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2024-02-22 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-12-05 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-10-13 | Ripresa | Piper Sandler | Overweight |
| 2023-02-28 | Iniziato | Cowen | Outperform |
| 2022-12-15 | Iniziato | Goldman | Buy |
| 2022-11-16 | Iniziato | Truist | Buy |
| 2021-12-21 | Iniziato | The Benchmark Company | Buy |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-01-05 | Iniziato | BMO Capital Markets | Outperform |
| 2021-01-05 | Iniziato | Berenberg | Buy |
| 2021-01-05 | Iniziato | Credit Suisse | Outperform |
| 2021-01-05 | Iniziato | SVB Leerink | Outperform |
| 2021-01-05 | Iniziato | Stifel | Buy |
Mostra tutto
Abcellera Biologics Inc Borsa (ABCL) Ultime notizie
What sparked AbCellera Biologics to soar over 9% after hours - MSN
AbCellera Biologics Inc. (ABCL) stock price, news, quote and history - Yahoo Finance UK
AbCellera Biologics Inc. (ABCL) Stock Price, News, Quote & History - Yahoo! Finance Canada
AbCellera (ABCL): Among the Stocks That Could 10x Over the Next 5 Years - Insider Monkey
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026 - PharmiWeb.com
Press Release: AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026 - 富途牛牛
5 Stocks That Could 10X Over the Next 5 Years - Insider Monkey
Aug Gainers: Why is AbCellera Biologics Inc stock going down2026 Final Week & AI Driven Stock Reports - baoquankhu1.vn
ABCL SEC FilingsAbcellera Biologics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Update Report: What is AbCellera Biologics Incs P E ratio telling usTrade Signal Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Tudor Investment Corp ET AL Makes New Investment in AbCellera Biologics Inc. $ABCL - MarketBeat
AbCellera: Dart-Board Approach Reflects Trading Premium (Upgrade) (NASDAQ:ABCL) - Seeking Alpha
Sentiment Watch: What hedge funds are buying AbCellera Biologics IncEarnings Overview Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
AbCellera Biologics (ABCL) Goldman Sachs 45th Annual Global Healthcare Conference summary - Quartr
AbCellera Biologics Inc. (ABCL) - minichart.com.sg
Aug Intraday: Is AbCellera Biologics Inc affected by consumer sentiment - baoquankhu1.vn
AbCellera Biologics Eyes Integrated Biotech Shift; ABCL635 Phase II Data Due in Q3 at Forum - MarketBeat
Is AbCellera Biologics Inc a potential multi bagger2026 Sector Moves & Smart Money Movement Tracker - baoquankhu1.vn
Bear Alert: Is AbCellera Biologics Inc part of any ETF2026 Key Lessons & AI Optimized Trading Strategy Guides - baoquankhu1.vn
AbCellera at KeyBanc Forum: Strategic Advances in Biotech By Investing.com - Investing.com Canada
New CMO Appointment Strengthens AbCellera Biologics Inc. (ABCL)’s Push Into Immunology and Beyond - MSN
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Average Rating of "Hold" from Analysts - MarketBeat
AbCellera Biologics Q1 2025 Earnings Preview - MSN
AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says - MarketBeat
AbCellera at TD Cowen Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
DNB Asset Management AS Buys Shares of 656,208 AbCellera Biologics Inc. $ABCL - MarketBeat
Holdings Thermopylae Increases Stake in AbCellera Biologics Inc - GuruFocus
Thermopylae adds AbCellera (ABCL) shares in open-market buy - Stock Titan
AbCellera (ABCL) Is Up 18.8% After Pivoting To Clinical Stage And Filing Share Offering - simplywall.st
Thermopylae Holdings adds AbCellera (ABCL) shares in $3.27 open-market buy - Stock Titan
AbCellera (ABCL) CFO adds 42,600 shares in open-market stock purchase - Stock Titan
A Look At AbCellera Biologics (ABCL) Valuation After Narrower Losses And Pipeline Progress - simplywall.st
Decoding AbCellera Biologics Inc (ABCL): A Strategic SWOT Insigh - GuruFocus
Why AbCellera (ABCL) Is Up 11.5% After Narrowing Losses And Expanding ESOP Share Capacity – And What's Next - Yahoo Finance
AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M - Insider Monkey
Abcellera Warns Growing Generative AI Use Raises Cybersecurity, Privacy, and Operational Risks - TipRanks
AbCellera Biologics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
AbCellera Biologics (ABCL) Q4 Loss Narrows To US$0.03 EPS And Tests Bearish Narratives - simplywall.st
Abcellera Biologics Inc Azioni (ABCL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):